Rhodotorula septicemia: case report and minireview  by Petrocheilou-Paschou, V et al.
lOO Clinical Microbiology and Infection, Volume 7 Number 2, February2001
K992740-1 had intermediate resistance to cefotaxime (MIC
16 mg/L), whereas K. pneumoniae K992806-3 was resistant to
cefotaxime (MIC 64 mg/L). Three strains were resistant to
ceftazidime and aztreonam, but the MICs were higher in E. coli
K992806-2, E. coliK992740-1, and K. pneumoniae K992806-3,
in that order. Sequence analysis revealed that blaTEM_17b was
more similar to blaTEM_lb than to blaTEM_la> and four of
seven silent mutations of blaTEM_17b were the same as those
of blaTEM_52 (at positions 469, 682, 863 and 985). Our findings
from the same patient appear to represent the in vivo evolution
of If-Iactamase genes (from blaTEM_lb to blaTEM_17b and from
blaTEM_17b to blaTEM_52) under the selective pressure of anti-
microbial therapy (especially cefotaxime), as was the case with
blasHv_8 [7].
ACKNOWLEDG MENTS
This work was supported by a research grant of the Korea
Science and Engineering Foundation (1999-2-211-002-5).We
would like to thank]. G. Sutcliffe, H. Hachler. T. Horii, G. A.
Jacoby and Y. Ishii for the generous gift ofreference If-Iactamase
genes.
REFERENCES
1. Kim J, Kwon Y, Pai H, Kim J, Cho D. Survey of Klebsiella
pneumoniae strains producing extended-spectrum tJ-Iactamases:
prevalence of SHV-12 and SHV-2a in Korea. ] Clin Microbial
1998; 36: 1446-9.
2. Bush K, Jacoby GA, Medeiros AA. A functional classification
scheme for tJ-Iactamases and its correlation with molecular
structure. Antimicrob Agents Chemother 1995; 39: 1211-33.
3. Lindberg F, Normark S. Sequence of the Citrobacter freundii OS60
chromosomal ampC tJ-Iactamase gene. EurJ Biochem 1986; 156:
441-5.
4. Rosenau A, Cattier B, Gousset N, Harriau 1',Philippon A, Quentin
R. Capnocytophaga ochracea; characterization of a plasmid-
encoded extended-spectrum TEM-17 tJ-Iactamase in the phylum
Flavobacter-Bacteroides. Antimicrob Agents Chemother 2000; 44: 760-2.
5. Sutcliffe JG. Nucleotide sequence of the ampicillin resistance gene
ofEscherichia coliplasmid pBR322. Proc Natl Acad Sci USA 1978; 75:
3737-41.
6. Goussard S, Courvalin P Sequence of the genes blaT-1B and blaT-2.
Gene 1991; 102: 71-3.
7. Rasheed JK, Jay C, Metchock B. Evolution of extended-spectrum
tJ-Iactam resistance (SHV-8) in a strain of Escherichia coli during
multiple episodes of bacteremia. Antimicrob Agents Chemother 1997;
41: 647-53.
Rhodotorula septicemia: case report and minireview
v Petrocheilou-Paschou1, 2', H. Prifti2, E. Kos tis1, C. Papadimitriou", M. A. Dimopoulos' and S. Siamatelopoulos'
IDepartment of Clinical Therapeutics, University of Athens School ofMedicine, 'Alexandra' Hospital, 80 V Sofias Avenue, 11528
Athens, and 2Department of Microbiology, 'Alexandra' Hospital, Athens, Greece
*Tel: + 301 7488941 Fax: + 301 81313 E-mail: mdimop@cc.uoa.gr
Accepted 26 November 2000
Rhodotorula, a yeast member ofthe family Cryptococcaceae, was
only recently recognized as a human pathogen especially affect-
ing immunocompromised patients [1]. To our knowledge, over
the last 40 years, no more than 40 cases ofrhodotornla infections
have been reported in patients with central indwelling vascnlar
catheters. We isolated Rhodotorula rubra from both the catheter
and the peripheral venous blood of a patient on azole prophy-
laxis. On this occasion, we reviewed the literature and the
limited experience with rhodo torula hospital infections in
Greece.
A 21-year-old female patient, with non-Hodgkin's lym-
phoma in second remission, underwent autologous peripheral
blood progenitor cell transplantation. A large peripheral
double lumen catheter was placed in the subclavian vein for
the collection and reinfusion of stem cells. The conditioning
regImen was gIven on days - 5 to - 1. The patient
received prophylactic oral ciprofloxacin 500 mg twice daily
and fluconazole 200 mg/day. Because of severe vomiting and
gastrointestinal mucositis, total parenteral nutrition was man-
datory. One day after stem cell reinfusion (day 1), the patient
developed grade 4 neutropenia on the WHO toxicity scale
(PMN count <100/IlL), and 3 days later (9 days after insertion
of the catheter) she became febrile. Blood cultures were
obtained from both the catheter sites as well as from the
antecubital vein. Ciprofloxacin was discontinued, and intrave-
nous ceftazidime, vancomycin and amikacin were started.
Microscopic examination ofall blood cnltures revealed budding
yeasts.
Blood cnltures were performed with the continuously mon-
itored non-invasive system BACTEC 9240 (Becton Dickinson
Medical Systems, Rutherford, NJ, USA). Blood specimens
were inoculated in BACTEC plus F aerobic and anaerobic
bottles (Becton Dickinson Microbiology Systems, Sporks,
Maryland, USA) and were incubated for a standard 7-day
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Figure 1 Culture of blood, on Sabouraud-dextrose agar, that yielded Rho-
dotorula rubra.
protocol or until the instrument gave a positive signal. The
yeasts recovered from blood cultures were subcultured on
Sabouraud-dextrose agar and incubated at 35°C for 48 h;
they were identified as Rhodotorula rubra according to colony
morphology and coral red pigment production (Figure 1),
microscopic characteristics on Gram stain, biochemical
reactions obtained by API ID 32C (BioMerieux, I'Etoile,
France), as well as urea production, carbon assimilation and
fermentation.
Antifungal susceptibility testing was performed using the
broth microdilution system 'Yeast one' sensititre (AccuMed
International Limited, East Grinstead, West Sussex, UK).
The MIC values (mg/L) of the following antifungal drugs
against the Rhodotorula isolate were: amphotericin B 0.25,
fluconazole >256, ketoconazole 0.25, 5-flucytosine 0.06,
and itraconazole 1. Candida parapsilosis ATCC 90018 was also
tested as a control, and MICs of the above antifungal agents
(mg/L) were 0.25, 1, 0.016, 0.06 and 0.06, respectively.
Fluconazole was discontinued and intravenous liposomal
amphotericin B was started with a daily dose of 3 mg/kg of
body weight. However, 3 days later, the patient remained
febrile, and blood cultures were again positive for the same
fungus, despite a PMN count of more than 1000/J-lL. Even-
tually, the central catheter was removed, and the following day
the patient became afebrile. Rhodotorulawas again isolated from
the tip of the removed catheter. Following the removal of the
catheter, treatment with liposomal amphotericin B was con-
tinued for a total of7 days and the patient was discharged from
the hospital, after complete hematologic recovery, without
further complications.
Concise Communications IOI
Rhodotorulawas traditionally considered to be a contaminant,
but within the last decade it has been progressively recoguized
that this yeast can cause infections, especially in immunocom-
promised patients with central venous catheters [1,2]. Rhodo-
torula rubra has been regarded as having lower virulence (about
15% mortality) in comparison with Candida spp. and Trichos-
poron spp., as has been reported by Krcmery et al in a recent
review [3]. It is thus an infrequent cause of infection, with ouly
12 culture-proven rhodotorula fungemia cases reported prior to
1984 [2]. More specifically, rhodotorula infection appears to
represent a rare complication of bone marrow transplantation,
with ouly one case reported in series of 1186 bone marrow
recipients between 1974 and 1989 [4]. In 1992, 23 catheter-
related cases of sepsis caused by this yeast were described in
cancer patients from one center [2], and since then another five
patients with fungemia have been reported in the English-
language literature [5-9]. In our country, cases of sepsis due to
Rhodotorulaare even rarer. This is the ouly case documented in
our hospital in the last 15 years. A case of fungemia following
surgery for colon carcinoma was recently reported from Greece
[10], and another one was included in a surveillance study
conducted among several hospitals in Athens during the last 2
years [11]. In the latter study, Rhodotorula was isolated from a
quadriplegic child.
Most of the reported infections were documented in cancer
patients with indwelling vascular catheters [2,5]; four of them
were neutropenic [2,5,9] and only two had positive blood
cultures from both catheter and peripheral vein [2,8]. Our
patient had a lymphoma, was severely neutropenic and had a
central venous catheter placed for stem cell collection and
reinfusion, as well as for total parenteral nutrition. Our patient
also had positive blood cultures obtained from the catheter, as
well as from a peripheral vein. As has been stressed by Kiehn et al
[2], Rhodotorula usually remains in the lumen of the catheter,
and blood cultures from peripheral veins are usually negative.
Severe neutropenia is the most likely cause ofthis dissemination,
as Fanci et al [7] suggested in their case report. Central vein
catheter has been recoguized as a major risk factor for rhodo-
torula fungemia. In the majority of the reported cases, indwel-
ling catheters had been placed 1-22 months prior to fungemia.
Our patient developed rhodo torula sepsis very early, ouly 9 days
after the catheter insertion. Although catheter insertion is a
specific risk factor for Rhodotorula fungemia, severe neutro-
penia and total parenteral nutrition combined possibly played a
supplementary role in the development of the septicemia [3].
The treatment of catheter-related Rhodotorula fungemia
remains controversial. Some authors believe that catheter
removal is not necessary for cure [1,2]. On the other hand,
in a small number of cases, catheter removal without antifungal
therapy was also curative. Our patient was febrile, and the
cultures still yielded Rhodotorula, 3 days after amphotericin B
introduction, while she became afebrile 1 day after removal of
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the catheter. Treatment with amphotericin B was continued for
a further 7-day course, as Kiehn et al [2] recommended in their
report. Our case strengthens the point of view that catheter
removal and administration of antifungal therapy appears to be
the optimal treatment. Liposomal amphotericin B was chosen,
because it is generally better tolerated than the amphotericin B
deoxycholate.
Our patient became fungemic despite fluconazole prophy-
laxis, and in vitro susceptibility testing performed with anti-
fungal drugs revealed that the Rhodotorula isolate was highly
resistant to fluconazole, as has also been reported by others
[10,12]. Regarding prophylactic treatment of immunocompro-
mised patients with fluconazole, it should be remembered that
widespread antifungal prophylaxis, although providing protec-
tion against sensitive organisms, also may allow the emergence
of more resistant isolates such as Rhodotorula spp.
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